IGM Biosciences, Inc.

NasdaqGS:IGMS Stock Report

Market Cap: US$76.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

IGM Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:IGMS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
23 Jul 25SellUS$18,457Mary HarlerIndividual14,501US$1.27
23 Jul 25SellUS$5,612Lisa DeckerIndividual4,409US$1.27
23 Jul 25SellUS$11,126Misbah TahirIndividual8,741US$1.27
16 Jun 25SellUS$1,825Mary HarlerIndividual1,522US$1.20
16 Jun 25SellUS$1,140Lisa DeckerIndividual951US$1.20
16 Jun 25SellUS$1,825Misbah TahirIndividual1,522US$1.20
16 Jun 25SellUS$583Steven WeberIndividual486US$1.20
14 May 25SellUS$2,090Steven WeberIndividual1,865US$1.12
14 Mar 25SellUS$9,015Mary HarlerIndividual7,329US$1.23
14 Mar 25SellUS$5,550Lisa DeckerIndividual4,512US$1.23
14 Mar 25SellUS$2,092Steven WeberIndividual1,701US$1.23
14 Mar 25SellUS$9,015Misbah TahirIndividual7,329US$1.23

Insider Trading Volume

Insider Buying: IGMS insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of IGMS?
Owner TypeNumber of SharesOwnership Percentage
Public Companies1,438,9752.39%
Individual Insiders1,526,2562.53%
VC/PE Firms3,255,8265.4%
Institutions7,747,82012.9%
Private Companies10,400,56417.3%
General Public10,917,74418.1%
Hedge Funds25,005,50241.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 80.12% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
24.6%
Baker Bros. Advisors LP
14,841,334US$18.8m0.17%0.13%
17.3%
Topsøe Holding A/S
10,400,564US$13.2m0%no data
16.9%
Redmile Group, LLC
10,164,168US$12.9m0.13%1.0%
5.4%
Artal Group S.A.
3,255,826US$4.1m-2.24%0.12%
4.2%
Glazer Capital, LLC
2,534,803US$3.2m0%0.26%
2.39%
Sanofi
1,438,975US$1.8m0%no data
1.71%
BlackRock, Inc.
1,030,124US$1.3m-2.22%no data
1.29%
Goldman Sachs Group, Investment Banking and Securities Investments
775,151US$984.4k0%no data
1.27%
The Vanguard Group, Inc.
767,154US$974.3k-12.4%no data
0.82%
State Street Global Advisors, Inc.
493,698US$627.0k7.45%no data
0.68%
M. Behrens Wilsey
412,535US$523.9k0.36%no data
0.54%
Mary Harler
323,680US$411.1k1,260%no data
0.45%
Fred Schwarzer
269,184US$341.9k7.58%no data
0.39%
AQR Capital Management, LLC
232,409US$295.2k1,800%no data
0.35%
Geode Capital Management, LLC
213,273US$270.9k-49.9%no data
0.31%
Northern Trust Global Investments
186,966US$237.4k-3.12%no data
0.23%
Two Sigma Investments, LP
139,770US$177.5k29.9%no data
0.2%
Bruce Keyt
120,921US$153.6k10%no data
0.2%
Verition Fund Management LLC
119,068US$151.2k0%no data
0.19%
William Strohl
115,602US$146.8k0%no data
0.17%
Bruce & Co Inc
100,000US$127.0k0%0.04%
0.17%
Eagle Bay Advisors LLC
99,635US$126.5k0%0.1%
0.15%
Jakob Topsoe
91,712US$116.5k0.91%no data
0.15%
Two Sigma Advisers, LP
90,500US$114.9k0%no data
0.15%
Charles Schwab Investment Management, Inc.
89,705US$113.9k-28.6%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/15 10:20
End of Day Share Price 2025/08/13 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IGM Biosciences, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael SchmidtGuggenheim Securities, LLC
Biren AminJefferies LLC
Roger SongJefferies LLC